

ASX Announcement

Regeneus Annual General Meeting Address by Executive Chairman John Martin

Sydney, Australia – 28 October 2014

On behalf of the Board I am pleased to welcome you to the 2014 Annual General Meeting of Regeneus, our second meeting as a publicly listed company.

Let me introduce my fellow Directors. To my right, Professor Graham Vesey, our CEO and co-founder; next to Graham is Dr Roger Aston, then Barry Sechos and lastly Associate Professor Ben Herbert, also a Regeneus co-founder.

Together with the company's committed and capable management and staff, the Board is intent on realising Regeneus' full potential, not only to deliver significant benefits to both human and animal health but also to justify shareholders' faith in Regeneus through enhancing the value of your investment in the company.

The Year in Review and FY15 Activity

This afternoon I will focus on the highlights of the past year's operational activities and share with you our plans for the future and specific goals for FY15 and beyond in a slide presentation which has been lodged on the ASX Markets Announcement Platform immediately prior to this meeting.

On behalf of the Board I thank the Regeneus executive management group and all of our employees and R & D partners for their hard work and passion over the past year. We all know that we are achieving something really important at Regeneus and we look forward to another year of building revenues, developing and launching products and passing more milestones.

Finally, may I thank you, our shareholders, for your continued support and commitment to the development of regenerative medicine.

ENDS

About Regeneus:

Regeneus Ltd (ASX: RGS) is a Sydney-based ASX listed regenerative medicine company that develops and commercialises stem cell and other biological therapies for the human and veterinary health markets with a focus on musculoskeletal and oncology conditions. The company has a marketed autologous (patient's cells) product using adipose (fat) derived stem cells to treat human osteoarthritis (OA), HiQCell, which has been used to treat over 1000 arthritic joints. The company plans to commence a clinical trial of allogeneic (donor cells) adipose stem cells to treat human OA in Q2 2015.

Regeneus' lead product for the veterinary health market is CryoShot, a clinical stage allogeneic adipose stem cell product for the treatment of canine and equine OA. CryoShot canine is scheduled for a US registration trial in Q4 2015. Regeneus has a clinical stage autologous therapeutic cancer vaccine, Kvax, which has commenced marketing trials in the US in Q4 2014. The company has also acquired the exclusive rights to commercialise the vaccine technology for human applications and plans to commence a first-in-man study in Q2 2015.

Contact for further information:**Investors:**

Sandra McIntosh
Company Secretary
Regeneus Ltd
T: +61 2 9499 8010
E: investors@regeneus.com.au or go to www.regeneus.com.au